Bimekizumab Application Scope

Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Treatment of active psoriatic arthritis (PsA) in adults.
Treatment of active ankylosing spondylitis (AS) in adults.
Treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adults.
Treatment of moderate to severe hidradenitis suppurativa (HS) in adults.

Bimekizumab Characteristics

Ingredients: Bimekizumab
Properties: Bimekizumab is a recombinant humanized IgG1 monoclonal antibody that selectively inhibits interleukin (IL)-17A and interleukin (IL)-17F, key cytokines involved in inflammatory processes.
Packaging Specification: Pre-filled syringe or pre-filled pen containing 160 mg/mL solution for subcutaneous injection.
Storage: Store refrigerated at 2°C–8°C. Do not freeze. Protect from light.
Expiry Date: As indicated on the product packaging.
Executive Standard: According to relevant pharmacopoeial and biologic product standards.
Approval Number: Varies by country.
Date of Revision: Varies by region.
Manufacturer: UCB Pharma S.A.

Guidelines for the Use of Bimekizumab

Dosage and Administration:
- Recommended Dose:
  - Plaque Psoriasis: 320 mg (two 160 mg injections or one 320 mg injection) at Weeks 0, 4, 8, 12, 16, then every 8 weeks. For patients ≥120 kg, consider 320 mg every 4 weeks after Week 16.
  - Psoriatic Arthritis: 160 mg every 4 weeks. Use plaque psoriasis regimen if coexistent moderate to severe plaque psoriasis.
  - Non-Radiographic Axial Spondyloarthritis: 160 mg every 4 weeks.
  - Ankylosing Spondylitis: 160 mg every 4 weeks.
  - Hidradenitis Suppurativa: 320 mg at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, then every 4 weeks.
- Administration: Administer subcutaneously in the abdomen, thigh, or upper arm. Avoid injecting into areas where the skin is tender, bruised, or damaged.
- Missed Dose: If a dose is missed, administer as soon as possible. Resume the regular dosing schedule thereafter.
Adverse Reactions:
- Common Adverse Reactions:
  - Upper respiratory tract infection
  - Oral candidiasis
  - Headache
  - Injection site reactions
  - Fatigue
- Serious Adverse Reactions:
  - Serious infections (e.g., fungal infections)
  - Hypersensitivity reactions
  - Inflammatory bowel disease exacerbation (rare)
Contraindications:
- Hypersensitivity to Bimekizumab or any excipients
- Active clinically significant infections, including tuberculosis
Precautions:
- Screen for tuberculosis prior to initiation.
- Monitor for signs of infection during treatment.
- Avoid live vaccines during therapy.
- Use with caution in patients with a history of chronic infections or inflammatory bowel disease.

Bimekizumab Interactions

Live Vaccines: Avoid concurrent use (due to increased risk of infection from the vaccine).
CYP450 Substrates (Narrow Therapeutic Index): Bimekizumab may normalize the formation of certain CYP450 enzymes that are suppressed by chronic inflammation. This could result in lower exposure of certain co-administered drugs metabolized by CYP450 (e.g., Warfarin, Cyclosporine). Therapeutic monitoring is advised when starting Bimekizumab with these types of medications.
Other Immunosuppressants: Caution is generally advised with other immunosuppressive agents due to the potential for increased risk of infection.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.